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Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a condition in which excess fat accumulates in hepatocytes.
Nonalcoholic steatohepatitis (NASH), a severe form of NAFLD in which inﬂammation and ﬁbrosis in the liver are noted, may
eventually progress to end-stage liver disease. Galectin-3, a β-galactoside-binding animal lectin, is a multifunctional protein.
This protein is involved in inﬂammatory responses and carcinogenesis. We investigated whether galectin-3 is involved in the
development of NASH by comparing galectin-3 knockout (gal3−/−) mice and wild-type (gal3+/+) mice with choline-deﬁcient L-
amino-acid-deﬁned (CDAA) diet-induced NAFLD/NASH. Hepatic injury was signiﬁcantly more severe in the gal3−/− male mice,
as compared to the gal3+/+ mice. Data generated by microarray analysis of gene expression suggested that galectin-3 deﬁciency
causes alterations in the expression of various genes associated with carcinogenesis and lipid metabolism. Through canonical
pathway analysis, involvement of PDGF and IL-6 signaling pathways was suggested in galectin-3 deﬁciency. Signiﬁcant increase of
CD14, Fos, and Jun, those that were related to lipopolysaccharide-mediated signaling, was candidate to promote hepatocellular
damages in galectin-3 deﬁciency. In conclusion, galectin-3 deﬁciency in CDAA diet promotes NAFLD features. It may be caused
by alterations in the expression proﬁles of various hepatic genes including lipopolysaccharide-mediated inﬂammation.
1.Introduction
Galectin-3 is a 30-kD mammalian lectin which has a C-ter-
minal carbohydrate-recognition domain and an N-terminal
domain comprising multiple repeat sequences rich in gly-
cine, proline, and tyrosine. It is expressed in various cells
such as epithelial cells and inﬂammatory cells. Galectin-3
performsmultiplefunctions,includingtheregulationofcell-
to-cell or cell-to-matrix adhesion [1–5], chemoattraction of
monocytes/macrophages [6], mediation of pre-mRNA splic-
ing [7], and protection against Fas- and staurosporine-in-
duced apoptosis associated with Bcl-2 expression [8].
During the development of human and mouse embryos,
galectin-3 is detectable in most types of cells, including
hepatocytes [9, 10]. In rats, the expression of galectin-3 was
found to be rapidly induced in the liver at 9 days after birth
and decreased to trace levels in adults [11]. Moreover, very
little galectin-3 mRNA was detected in the livers of normal
adult rats [12]. In human [13] and mouse livers, galectin-3
expression was not detected in normal hepatocytes, whereas
it was found to be prominent in the bile duct epithelial
cells and Kupﬀer cells [14, 15]. On the other hand, it was
found that galectin-3 expression was aberrantly induced in
the cytoplasm of the periportal hepatocytes of adult rat liver
exhibiting inﬂammation caused by CCl4 administration [12]
and in the hepatocytes surrounding regenerating nodules
in human cirrhotic liver [15]. In addition, the results of a
previous study showed that the expression of galectin-3 was2 The Scientiﬁc World Journal
signiﬁcantly upregulated in activated rat hepatic stellate cells
[16]. Galectin-3 expression was also found to be required for
the myoﬁbroblast activation and matrix production medi-
atedbytransforminggrowthfactorβ (TGF-β)[17].Recently,
we demonstrated that disrupted galectin-3 expression in
male mice leads to the development of nonalcoholic fatty
liver disease (NAFLD) and hepatocellular carcinoma (HCC)
with liver ﬁbrosis [18, 19]. Taken together, these results sug-
gest that galectin-3 plays some important roles in liver hom-
eostasis. However, its role in liver pathology, particularly
NAFLD, is largely unknown.
NAFLD is increasingly recognized as a liver disorder that
may eventually progress to end-stage liver disease, includ-
ing HCC [20–22]. NAFLD is the preferred term for describ-
ing a liver condition that includes a wide spectrum of con-
ditions from simple steatosis to steatohepatitis, advanced
ﬁbrosis, and cirrhosis in the liver. The diagnostic criteria for
nonalcoholicsteatohepatitis(NASH)arecontinuouslyevolv-
ing and based on histological ﬁndings [23, 24]. The most
common histopathological features of NASH include hep-
atocellular steatosis and ballooning degeneration, mixed
acute and chronic lobular inﬂammation, and perisinusoidal
ﬁbrosis in the zone 3 regions. Although NASH can be caused
by a variety of factors, its occurrence is frequently associated
with obesity, type II diabetes, hyperlipidemia, and metabolic
syndrome [20, 25–27]. The pathogenesis of NASH is poorly
understood; however, a “two-hit theory” has been proposed
[28]. This theory suggests that, in addition to steatosis (the
ﬁrst “hit”), certain other factor(s) (the second “hit”) are
required for the development of steatohepatitis. Above all,
involvement of lipopolysaccharide is broadly accepted as a
candidate of trigger. Recent studies using animal models of
NAFLD have also provided new insights into the molecular
and physiologic alterations that contribute the ﬁrst and
second hits in the progression of NAFLD to end-stage liver
disease [29, 30]. Various genes and their expression proﬁles
associated with NAFLD have recently been analyzed and
identiﬁed [31–34].
In the present study, we hypothesized that galectin-3
deﬁciency increases hepatic injury in mice with NASH in-
duced by a choline-deﬁcient l-amino-acid-deﬁned (CDAA)
diet, because galectin-3 is a negative regulator of lipopoly-
saccharide-mediated inﬂammation [35]. We report herein
that enhancement of lipopolysaccharide signaling pathway
involving CD14, Fos, and Jun was observed in galectin-
3-deﬁcient mice with CDAA diet. Lipopolysaccharide-me-
diated signaling may not only be a trigger but also be a pro-
moter of NAFLD.
2.MaterialsandMethods
2.1. Animals and Experimental Protocol. Galectin-3 knock-
out (gal3−/−) mice and their wild-type littermates (gal3+/+)
generated on a CD1 background were generously provided
by Dr. Liu’s group [36]. The mice were housed under
pathogen-free conditions in a temperature-controlled room
with a 12h light/dark illumination cycle. All the procedures
for handling animals were in accordance with the Guide for
the Care and Use of Laboratory Animals and approved by
theCommitteeonAnimalExperimentationoftheUniversity
of Toyama. In order to determine the maximum duration
required to detect hepatic changes in mice fed the CDAA
diet (Dyets, Bethlehem, PA, USA; product no. 518753), a
pilot study was conducted in 8- to 10-week-old male mice
fed over a period of 0–12 weeks to examine the eﬀects
of the diet on the serum alanine transaminase (ALT) and
aspartate transaminase (AST) levels and on liver steatosis,
inﬂammation, and ﬁbrosis. The severity of liver steatosis,
inﬂammation, and ﬁbrosis observed after 8 weeks of CDAA
diet was similar to that observed at 12 weeks; therefore, we
determined that maximum duration fed CDAA diet was 8
weeks in this study. Thus, groups of 4 to 6 male gal3−/− and
gal3+/+ mice were fed the CDAA diet and sacriﬁced after 0,
2, 4, and 8 weeks. The body weights were recorded at the
start and end of each experimental period. Blood samples
were collected for serum analysis. The livers of the mice were
rapidly excised, rinsed in ice-cold saline, and weighed. Liver
samples were snap-frozen in liquid nitrogen and maintained
at −80◦C until analysis. A portion of each liver was ﬁxed in
10% formalin for histopathological examination.
2.2. Evaluation of Liver Injury. The serum ALT and AST
levels were measured using a transaminase CII-Test kit
(Wako Pure Chemical Industries, Osaka, Japan) according
to the manufacturer’s protocol. Liver samples were minced
in ice-cold PBS (pH 7.4) and homogenized in the buﬀer
at a concentration of 1:10 (w:v). After centrifugation at
5,500rpmfor10minat4◦C,thesupernatantswerestoredfor
subsequent determination of the total liver triglyceride levels
using a commercially available kit (Wako E-test triglyceride
kit; Wako Pure Chemical Industries). Data were expressed as
milligrams of triglyceride per gram of wet liver weight.
2.3. Histological Analysis. The formalin-ﬁxed liver tissue was
processed, and 4-μm-thick paraﬃn sections of the liver
samples were stained with hematoxylin and eosin for his-
tological analysis. Steatohepatitis was scored by experienced
pathologists (K. N. and K. T.) in a blinded manner. Hepatic
steatosis was graded as follows according to the percentage
of lipid-laden hepatocytes: 0, 0%; 1, 0–33%; 2, 33–67%; 3,
67–100%. Necroinﬂammation was graded on the basis of
the number and size of the necroinﬂammatory lesions in
representative liver sections as follows: 0, none; 1, mild; 2,
moderate; 3, severe [37].
2.4. RNA Preparation. A liver sample from one mouse in
each group fed CDAA diet for 8 weeks was homogenized,
and total RNA was extracted using the RNeasy Total RNA
Extraction kit (Qiagen, Valencia, CA, USA) and treated with
DNase I (RNase-free DNase kit; Qiagen, Valencia, CA, USA)
for 15min at room temperature to remove residual genomic
DNA.
2.5. Aﬀymetrix GeneChip Hybridization. In order to investi-
gate the gene expression proﬁles, the Aﬀymetrix mouse ex-
pression 430A array was used. Sample preparation for thisThe Scientiﬁc World Journal 3
Table 1: Primer pairs and probe sequences used for real-time PCR reactions.
Target Sequences
Pdgfrb
F: 5 -ACCTGTTCATTTTTGTCACGGATG-3 
R: 5 -TTCTTCTCATGTAGCGTCACCTC-3 
Probe: 5 -6FAM-CGACAATTCCGTGCCGAGTGACAGACC-TAMRA-3 
Stat 1
F: 5 -AGGTGTTGTCAGATCGAACCTTC-3 
R: 5 -CATGCACGGCTGTCGTTCTA-3 
Probe: 5 -6FAM-CTCTTCCAGCAGCTCATTCGGAGCTC-TAMRA-3 
Csnk2a2
F: 5 -AGCCCGGAGGCCCTAGA-3 
R: 5 -TTTGGCGGTCAATCTCTGTTG-3 
Probe: 5 -6FAM-TCTTGACAAGCTCCTGCGGTACGACC-TAMRA-3 
Fos
F: 5 -CCTGAGCCCAAGCCATCC-3 
R: 5 -GTCATCAAAGGGTTCTGCCTTC-3 
Probe: 5 -6FAM-CGTTGCTGATGCTCTTGACTGGCTCCA-TAMRA-3 
Jun
F: 5 -ACTGCAAAGATGGAAACGACCT-3 
R: 5 -AGCCGTAGGCACCGCTCT-3 
Probe: 5 -6FAM-CGATGCCCTCAACGCCTCGTTC-TAMRA-3 
Cd14
F: 5 -CCGAAGCCAGATTGGTCCAG-3 
R: 5 -CACACGCTTTAGAAGGTATTCCAG-3 
Probe: 5 -6FAM-CCGCCGTACAATTCCACATCTGCCG-TAMRA-3 
GAPDH
F: 5 -AGGGATGATGTTCTGGGCAG-3 
R: 5 -AGACTGTGGATGGCCCCTC-3 
Probe: 5 -6FAM-ACGGCCATCACGCCACAGCTTT-TAMRA-3 
Pdgfrb: platelet-derived growth factor receptor, beta polypeptide; Stat1: signal transducer and activator of transcription 1; Csnk2a2: casein kinase 2, alpha
prime polypeptide; Fos: FBJ osteosarcoma oncogene; GAPDH: glyceraldehyde-3-phosphate dehydrogenase.
analysiswasperformedaccordingtotheproceduredescribed
in the Aﬀymetrix GeneChip Expression technical manual.
Brieﬂy, 5μg of total RNA was used to synthesize dou-
ble-stranded cDNA by using a GeneChip Expression 3 -
Ampliﬁcation Reagents One-cycle cDNA Synthesis Kit (Aﬀy-
metrix, Santa Clara, CA, USA). Biotin-labeled cRNA was
then synthesized using GeneChip Expression 3 -Ampliﬁca-
tion Reagents for IVT Labeling (Aﬀymetrix). After frag-
mentation, the biotinylated cRNA was hybridized to a
GeneChip array at 45◦C for 16h. The chip was washed,
stained with streptavidin-phycoerythrin, and scanned with
a GeneChip scanner 3000 (Aﬀymetrix), and the results
were analyzed using the GeneChip Analysis Suite Software
(Aﬀymetrix). Hybridization intensity data were represented
as presence/absence calls for each gene, and the diﬀerences
in gene expression between experiments were detected by
comparison analysis. The data were further analyzed using
GeneSpring version 7.3 (Silicon Genetics, Redwood City,
CA, USA) to extract signiﬁcantly expressed genes and deter-
mine their ontology, including biological processes, cellular
components, and molecular functions. Genes were consid-
ered upregulated or downregulated if there was 2-fold or
greaterdiﬀerenceintheirexpressionbetweenthegal3−/− and
the gal3+/+ mice.
2.6. Functional Network, Gene Ontology, and Canonical Path-
way Analyses. The genes identiﬁed by GeneSpring were
used for functional network and gene ontology analyses.
Gene accession numbers were imported into the Ingenuity
Pathway Analysis version 3.1 (IPA) software (Ingenuity Sys-
tems, Mountain View, CA, USA), and the gene products
were categorized using the software on the basis of their
hepatic location and cellular localization and the reported or
suggested biochemical, biological, and molecular functions.
The genes were then mapped to the genetic networks
availableintheIngenuitydatabaseonthebasisoftheirscore-
wise ranking, and the probability that a collection of genes
is to the same as or greater than the number of genes in
a network was a matter of chance. A score of 3 obtained
randomly indicates that there is a 1/1000 chance that the
identiﬁed genes are a part of the network. Therefore, scores
of 3 or higher have a 99.9% conﬁdence level of not having
been generated randomly. This score was used as the cutoﬀ
for identifying gene networks.
2.7. Real-Time PCR. Six genes included in the highly signi-
ﬁcant canonical pathways (PDGF signaling and IL-6 signal-
ing) were chosen for further validation by real-time PCR.
Total RNA was isolated from the liver samples using Iso-
gen reagent (Nippon Gene, Toyama, Japan). cDNA was
synthesized from 400ng of hepatic mRNA by using TaqMan
Reverse Transcription Reagents (Applied Biosystems, Tokyo,
Japan). PCR reactions and analyses were carried out using an
Mx3000PQPCRSystem(Stratagene,LaJolla,CA,USA)with
denaturation for 10min at 95◦C, followed by 50 PCR cycles
of denaturation at 95◦C for 30s, annealing at 55◦Cf o r1m i n
and extension at 72◦C for 30s. All primers and probes used
for analysiswere designed at Nipppon EGT (Toyama, Japan).
The primer and probe sequence details are given in Table 1.
The amount of mRNA was calculated using glyceraldehydes-
3-phosphate dehydrogenase (GAPDH) as the endogenous
control.4 The Scientiﬁc World Journal
Table 2: Eﬀect of CDAA diet on serum ALT, serum AST, and liver triglyceride levels in the gal3+/+ and gal3−/− mice.
CDAA diet consumption
0wk 2wk 4wk 8wk
Serum ALT (IU/L) Gal-3+/+ 26.9 ± 4.3 48.2 ± 9.8 89.9 ± 33.3 64.2 ± 17.5
Gal-3−/− 19.7 ± 1.0 109.6 ± 18.3∗ 151.2 ± 45.6 260.9 ± 101.6
Serum AST (IU/L) Gal-3+/+ 78.6 ± 7.6 80.7 ± 10.7 117.6 ± 27.3 75.7 ± 9.5
Gal-3−/− 78.5 ± 11.5 114.9 ± 15.1 153.7 ± 26.6 192.1 ± 39.9∗
Liver triglyceride (mg/g) Gal-3+/+ 13.3 ± 0.5 51.7 ± 3.4 64.9 ± 5.6 75.1 ± 1.7
Gal-3−/− 15.7 ± 1.0 58.1 ± 4.1 66.0 ± 4.0 88.1 ± 10.7
R e s u l t sa r ee x p r e s s e da sm e a n± SEM of the values from 4–6 mice in each group. ∗P<0.05 in comparison with gal3+/+ mice. CDAA: choline-deﬁcient l-
amino-acid-deﬁned diet; ALT: alanine aminotransferase; AST: aspartate aminotransferase.
2.8. Statistical Analysis. T h ev a l u e sw e r ee x p r e s s e da sm e a n s
±SEM.ThemeanswerecomparedusingtheMann-Whitney
U-test. P<0.05 was considered statistically signiﬁcant.
3. Results
3.1. Eﬀect of CDAA Diet on Liver Injury in Gal3−/− Mice.
Mice fed the CDAA diet showed an increase in serum ALT
and AST levels and liver triglyceride levels at week 2, and
the levels remained elevated up to week 8. The serum ALT
and AST levels were determined to be signiﬁcantly higher
in the gal3−/− mice, as compared to the gal3+/+ mice after
either 2 or 8 weeks of subjection to the CDAA diet (P<0.05)
(Table 2), whereas the increase in the liver triglyceride levels
in the gal3−/− mice was not signiﬁcant diﬀerence compared
to the gal3+/+ mice.
3.2. Eﬀe c to fC D A AD i e to nH e p a t i cM o r p h o l o g yi nG a l 3−/−
Mice. After2weeksofCDAAdietconsumption,macrovesic-
ular steatosis involving lobular zones 1 and 2 was observed
for both mice. The hepatocytes were swollen with mild-
to-moderate micro- and macrovesicular steatosis and mild
lobular and portal necroinﬂammation, which were more
severeinthegal3−/− mice(Figures1(c)and1(d)).In4weeks,
steatosis was further severe in the gal3−/− mice (Figures 1(e)
and 1(f)). The degree of steatosis after 2 or 4 weeks was
signiﬁcantly higher in the gal3−/− mice (P<0.05) (Table 3),
and the degree of necroinﬂammation after 2 weeks was also
signiﬁcantly higher in the gal3−/− mice (P<0.05) (Table 3).
In 8 weeks, both mice showed further severe steatosis and
moderate lobular and portal necroinﬂammation (Figures
1(g) and 1(h)).
3.3. Aﬀymetrix GeneChip Analysis of Genes in CDAA Diet-
Induced NAFLD. The expression of 22,625 mouse tran-
scripts was detected using the Aﬀymetrix mouse expression
430A array. In analysis of liver samples from the mice after
8 weeks of the CDAA diet, we identiﬁed 460 probes whose
expressionwasupregulatedby>2-foldand185probeswhose
expression was downregulated by >2-fold in gal3−/− mice
compared to the gal3+/+ mice.
3.4. Functional Network and Gene Ontology Analysis. To fur-
ther reﬁne our study, we investigated the biological inter-
actions of the 645 genes identiﬁed by the GeneChip analysis
using the IPA tool. We found that these 645 genes mapped to
genetic networks and had functional relationships. We also
identiﬁed 37 genetic networks in the livers of the gal3−/−
mice. Of these 37, 24 were highly signiﬁcant in that they
included more of the identiﬁed genes than expected by
chance. Networks with high scores (>15) included more
than half the identiﬁed genes (these are listed in Table 4),
which are associated with cancer, cell death, cellular assem-
bly and organization, cellular function and maintenance,
organismal injury and abnormalities, carbohydrate and lipid
metabolism, and so forth. We also performed gene ontology
analysis using the IPA tool and identiﬁed 73 categories as
signiﬁcant (data not shown).
3.5. Canonical Pathway Analysis. In the canonical pathway
analysis, we identiﬁed 2 signiﬁcant pathways (PDGF sig-
naling and IL-6 signaling pathways) in the liver samples of
gal3−/− mice at after 8 weeks on the CDAA diet (Figure 2).
3.6. Validation of Gene Expression with Real-Time PCR. In
order to conﬁrm the results of the Ingenuity pathway anal-
ysis, we measured the expression of 6 genes included in
the highly signiﬁcant canonical pathways. The genes in the
PDGF signaling and IL-6 signaling pathway include Pdgfrb,
Stat1, Csnk2a2, Fos, Jun,a n dCd14.m R N A sf o rFos, Jun,
and Cd14 were signiﬁcantly increased in gal3−/− mice
fed the CDAA diet compared to the gal3+/+ mice (P<
0.05) (Figure 3). Interestingly, these were key molecules
of lipopolysaccharide-mediated inﬂammation. mRNAs for
Pdgfrb, Stat1,a n dCsnk2a2 were also increased, but not
signiﬁcantly.
4. Discussion
Our results demonstrated that a deﬁciency in galectin-3 re-
sulted in an increase in hepatic injury in CDAA diet-in-
duced NAFLD. Additionally, the data we obtained by micro-
array analysis of gene expression suggested that galectin-
3 deﬁciency, in the background of CDAA diet-induced
NAFLD/NASH, may cause alterations in the expression of
various genes associated with cancer, cell death, cellular as-
sembly and organization, cellular function and maintenance,
organismal injury and abnormalities, and carbohydrate andThe Scientiﬁc World Journal 5
Gal3+/+
(a)
Gal3−/−
(b) (c)
(d) (e) (f)
(g) (h)
Figure 1: Representative photomicrographs showing the eﬀect of choline-deﬁcient l-amino-acid-deﬁned (CDAA) diet on liver histology in
gal3+/+ and gal3−/− mice. (a) and (b) are week 0 of CDAA diet (Control). In both mice, histopathological diﬀerences were not observed. (c)
and (d) are week 2. (e) and (f) are week 4. (g) and (h) are week 8 (hematoxylin and eosin staining, original magniﬁcation ×100).
Table 3: Eﬀect of CDAA diet and galectin-3 deﬁciency on the severity of hepatic steatosis and necroinﬂammation.
CDAA diet consumption
0wk 2wk 4wk 8wk
Steatosis Gal3+/+ 0.0 ± 0.0 0.6 ± 0.5 1.5 ± 0.6 2.3 ± 1.0
Gal3−/− 0.0 ± 0.0 2.0 ± 0.7∗ 2.8 ± 0.5∗ 2.8 ± 0.5
Necroinﬂammation Gal3+/+ 0.0 ± 0.0 0.6 ± 0.5 1.5 ± 0.6 2.0 ± 0.0
Gal3−/− 0.0 ± 0.0 1.8 ± 0.4∗ 1.8 ± 0.5 2.0 ± 0.0
The severity of both hepatic steatosis and necroinﬂammation was scored on a scale of 0–3, as described in Materials and Methods. Results are expressed as
mean ± SEM of the values from 4–6 mice in each group. ∗P<0.05 in comparison with gal3+/+ mice.
lipid metabolism. On the basis of our results, we were able
to propose several potential mechanisms underlying the
increase in hepatic injury observed in gal3−/− mice. The
ﬁrst possible mechanism is an increase in hepatocyte apop-
tosis. Previous studies have demonstrated that hepatocyte
apoptosis was signiﬁcantly increased in NASH [38–40].
Furthermore, Yang et al. reported on the protective eﬀects of
galectin-3 against Fas- and staurosporine-induced apoptosis
associatedwithBcl-2expression[8].Inourstudy,microarray
analysis revealed that the expression of genes associated
with cell death signiﬁcantly increased in the gal3−/− mice
compared to the gal3+/+ mice. These data suggest that
galectin-3playsanimportantroleasanantiapoptoticprotein
in hepatocytes aﬀected by CDAA diet-induced NAFLD.
In the canonical pathway analysis and validation of
gene expression with real-time PCR, we observed that the
expression of components of the PDGF and IL-6 signaling
pathways were signiﬁcantly ampliﬁed in the liver of the
gal3−/− mice after 8 weeks of the CDAA diet. As members
of the PDGF ligand family are known to play important
roles in cellular proliferation and migration, this ﬁnding
provided second possible mechanism behind the increased
hepaticinjuryobservedingal3−/− mice.Werecentlyreported
ac a s eo fs e v e r eﬁ b r o s i sa ﬀecting multiple organs caused
by neonatal PDGF overproduction [41]. In this case, the
PDGF-β receptor was found to be overexpressed in all the
ﬁbrotic organs, including the liver. Moreover, a previous
study showed that PDGF-C transgenic mice had enlarged
livers associated with increased ﬁbrosis, steatosis, cell dys-
plasia, and HCC [42]. These studies indicated that the
overexpressionofPDGFanditsreceptorinducesanumberof
proﬁbrotic pathways, suggesting that this growth factor acts6 The Scientiﬁc World Journal
Table 4: Genetic networks with high scores (>15) in gal3−/− mice with CDAA diet-induced NAFLD.
Network Genetic in Ingenuity networksa Score Focus genes Top functions
1
ACTG1, ANXA2, AP3D1, CA3, CD36, CD151,
CEACAM1, COTL1, CTSB, DNMT3A, ETS2, FOS,
GAS1, GSTA5, GSTM3, HNRPAB, IFRD1, ITGA2B,
JUN, MT1A, MT2A, MTF1, NMI, PBX2, RBM39,
RBP1, RPL39, S100A10, SERPINA3G, SLPI, SPP1,
TGM2, TMED10, TTRAP, TUBB2A
49 35 Cancer, cell death, cellular assembly and
organization
2
BAG3, BMPR1A, C5ORF13, CD2AP, COL1A1,
COL3A1, DIO1, DNAJB1, HDAC3, HSP90AA1,
HSPA8, HSPA1A, HSPH1, IFIH1, IRF3, KLF6, KPNA4,
LIFR, MBD1, P4HA1, PDGFC, PDGFRB, PPP1CB,
PTPN2, RHOB, RND3, ROCK1, SERPINH1, STAT1,
TANK, TBK1, TFRC, TGFBR2, TGTP, USP18
49 35
Cellular function and maintenance,
dermatological diseases and conditions,
organismal injury and abnormalities
3
ABCB11, ABCC3, BRD8, CDC20, CDH1, CPT1A,
CSNK2A2, CYP3A5, CYP4A22, CYP7A1, DLG1,
DNAJB4, DUSP6, FOXA1, G6PC, GADD45A,
GADD45G, GCK, HNRPH2, IGHM, INSIG2, IQGAP1,
LCN2, LGALS1, MAP3K4, PCK1, PPARGC1B, PTPRC,
RXRA, SCD, SMAD4, SQLE, SSRP1, SUB1, TMSB4X
49 35 Carbohydrate metabolism, cell death, cancer
4
ACSL4, AFP, ALDOC, ARF6, ARMET, CES1, COL5A2,
DUSP6, EGLN3, ENPP1, ERBB2, GJA1, HAS2, HGF,
HIF1A, HRAS, LCN2, LDHA, LGALS1, NDST1, NID1,
P D L I M 1 ,P G A M 1 ,P G F ,P L O D 1 ,P Q L C 1 ,P R D X 2 ,
RHOB, S100A4, SPRY2, SQLE, TMSB4X, TSC22D1,
TSC22D4, UCRC
20 21 Cancer, cellular movement, reproductive
system disease
5
ABCB1, ATF3, ATR, CASP4, CCNG1, CEBPD, CHUK,
CSF1R, DUSP1, FOXO3A, GBP4, GPIAP1, GSTM5,
H2AFZ, HSP90AA1, IFIT1L, ISG15, MCM2, MCM3,
MCM4, MCM6, MDM2, NOX4, PDCD6IP, POLB,
PPP2R4, RALGPS2, SON, SPP1, STRN3, SUMO1,
TANK, TP53, UBQLN1, WT1
19 20 Cancer, cell cycle, reproductive system disease
6
ANXA2, CD14, CIITA, COL4A2, COL6A1, COL6A2,
COL6A3, CREB1, ELN, EMILIN1, FGF10, GNAS,
IRF7, LDHA, MAPKAPK2, MFI2, NCL, OAT, OPRM1,
PCSK1, PITPNB, PLEKHC1, PTHLH, S100A11, SCD,
SCOTIN, SEC63, SFTPB, SSTR2, TGFB1, TGM1, TH,
TMEM123, TNFRSF10A, VNN1
17 19
Genetic disorder, skeletal and muscular
disorders, dermatological diseases and
conditions
7
ACVR1, AKAP12, CD14, CD53, CEACAM5, CEBPA,
CPB2, CSF1R, CYP3A5, DDIT3, EPAS1, FCGR1A,
GAL, HP, IGSF1, IK, IL6, INHBA, INHBC, INHBE,
ITGA2B, LGALS4, LOX, PGD, PSCDBP, PTPRC,
PTPRZ1, SAA1, SLCO1A1, SOAT1, SPBC25, STAR,
TRIB1, UCP1, USP52
17 19 Lipid metabolism, molecular transport, small
molecule biochemistry
8
ALDOB, APOM, ARPC4, ATP6V1E1, CD14, CD36,
CEBPB, CPS1, CSF3, CSTB, CXCL6, CYP24A1,
CYP4A22, CYP7A1, ELOVL3, FABP3, FGF19,
HCA112, LCN2, LEP, MBOAT5, NFKBIZ, NRG1,
ORM1, PDK4, PPARA, PTGER4, SCD, SLC10A2,
SLC20A1, SRXN1, TNFSF11, TRAF6, UGP2, ZNF274
17 19 Carbohydrate metabolism, molecular
transport, small molecule biochemistry
aGenes colored red or green are those identiﬁed by microarray analysis as upregulated and downregulated, respectively.
as an initiator of ﬁbrosis [42]. We speculated that galectin-
3 deﬁciency might lead to the higher expression of genes
related to the PDGF signaling pathway and consequently
accelerate the development of various pathological condi-
tions such as ﬁbrosis and carcinogenesis in patients with
NAFLD/NASH.
In a recent landmark study, Cai et al. demonstrated that
hepatic IL-6, a major proinﬂammatory cytokine, is markedly
expressed in animal models of NAFLD [43]. Moreover,
Wieckowska and coworkers found signiﬁcant increase in he-
patic IL-6 expression in NASH patients [44]. In the present
study, the expression of genes involved in the IL-6 signaling
pathway was signiﬁcantly higher in the gal3−/− mice. These
data suggest that galectin-3 deﬁciency may accelerate the
hepatic IL-6 signaling pathway, leading to an increased
inﬂammatory response, steatosis, and, ﬁnally, steatohepatitisThe Scientiﬁc World Journal 7
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Figure 2: The canonical pathways of the PDGF and IL-6 signaling. These pathways were signiﬁcantly identiﬁed in the complete data set.
The genes indicated in red are those that were upregulated; those indicated in white are not user speciﬁed but were incorporated into the
network since they shared functional relationships with the upregulated genes.
thus, providing a third possible mechanism behind the
increased hepatic injury observed in gal3−/− mice. Amongst
related molecules of IL-6 signaling pathway, CD14, Fos,
and Jun were signiﬁcantly increased in gal3−/− mice. These
molecules were key molecules of lipopolysaccharide signal-
ing.Itisbroadlyacceptedthatlipopolysaccharideisoneofan
important trigger of NAFLD. In 8 weeks of CDAA diet, there
are no signiﬁcant pathological changes between gal3−/− and
gal3+/+ mice, while the titer of ALT and AST was quite high
in gal3−/− mice. We hypothesized that lipopolysaccharide-
mediated signaling may not only be a trigger but also be
a promoter of NAFLD. Galectin-3, which is a negative reg-
ulator of lipopolysaccharide-mediated inﬂammation, may
be eﬀective to inhibit disease promotion of NAFLD/NASH.
Treatment of NAFLD by recruiting galectin-3 should be
examined using animal model of NAFLD in further study.
Previous studies have demonstrated that NASH can
progress to cirrhosis and eventually to HCC [45, 46]; how-
ever, its carcinogenetic mechanisms are largely unknown.
Although several animal models have been proposed in
order to understand the pathogenesis of NAFLD [47], the
possible neoplastic transformation that characterizes end-
stageNASHhasbeendevelopedinonlyafewmodels,includ-
ing aged gal3−/− mice [18, 48]. In the functional network
and gene ontology analysis, we identiﬁed networks with
high scores (>15), wherein more than half of the identiﬁed8 The Scientiﬁc World Journal
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Figure 3: Comparison with mRNA levels of the altered genes in
the signiﬁcant canonical pathway (PDGF signaling and IL-6 sig-
naling).Theselevelsweredeterminedbyreal-timePCR,normalized
to glyceraldehydes-3-phosphate dehydrogenase (GAPDH), and ex-
pressed as fold induction relative to the gal3+/+ mice. The values are
expressed as mean ± S E Mo ff o u rm i c ei ne a c hg r o u p .( ∗P<0.05).
genes were associated with cancer, cell death, cellular assem-
bly and organization, cellular function and maintenance,
organismal injury and abnormalities, and carbohydrate and
lipid metabolism. Therefore, we hypothesize that galectin-3
deﬁciencyundertheconditionofNAFLD/NASHcontributes
to liver carcinogenesis.
In conclusion, our study demonstrated that a deﬁciency
in galectin-3 increases hepatic injury in mice with CDAA
diet-induced NAFLD/NASH. Recruitment of galectin-3 may
be a new target of the treatment of NAFLD/NASH.
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